Lana Medicalشركة لانا الطبية
- Price
- 2.95 SAR
- Fair value
- 0.51 SAR
- Discount to fair value
- −478%
- Mkt cap
- 159.30M
- P/E
- 59.1×
- P/B
- 2.45×
- EV
- 183.84M
- ROE
- 4.1%
- Net margin
- 2.9%
Current price2.95SAR
Fair value (est., median)0.51SAR
UndervaluedFair valueOvervalued
+478.2% above fair valueWould need to fall ~82.7% to reach fair value.
Median ofGraham 1.21Residual Income 0.23Earnings Power 0.51
Health Check
23.9
Overall / 100
Good (66+)Caution (40–65)Risk (<40)
Rewards
—
Risks
- Trades 478.2% above estimated fair value.
- Low fair-value confidence — methods disagree or data is thin.
Scores are computed automatically from the real financial statements (Value from fair value; the rest from growth, profitability, balance sheet and dividends). A decision aid, not investment advice.
Price, corporate actions & news
Demo series
D — DividendS — Split▲ good · ▼ bad newstap a marker for details
Growth & profitability
Revenue, net income and margin.
RevenueNet incomeNet margin %tap a bar for figures
Key figures
Covers 4 years · FY2022–FY2025
| Metric | FY'22 | FY'23 | FY'24 | FY'25 |
|---|---|---|---|---|
| Revenue | 40.80M | 48.63M | 84.09M | 92.30M |
| Net Income | 5.49M | -1.93M | 12.46M | 2.70M |
| Net Margin | 13.5% | -4.0% | 14.8% | 2.9% |
| Operating Cash Flow | 5.60M | 1.02M | 393.2K | -5.64M |
| OCF Margin | 13.7% | 2.1% | 0.5% | -6.1% |
| Capital Expenditure | — | 3.66M | 4.12M | 4.73M |
| Free Cash Flow | 5.60M | -2.64M | -3.73M | -10.37M |
| FCF Margin | 13.7% | -5.4% | -4.4% | -11.2% |
| FCF Conversion | 101.9% | -136.9% | -29.9% | -384.5% |
| EPS (Diluted) | 0.10/sh | -0.04/sh | 0.23/sh | 0.05/sh |
| Dividend / Share | — | — | — | — |
Dividend return (if you buy today)
This company doesn’t currently pay a dividend, so there’s no income return to project. The fair-value gauge above covers the price side.
Dividend history
Dividend / share & historical yield (SAR).
No dividend history — this company doesn’t currently pay a dividend.
Corporate actions
SStock Split
10×2025-11-13
SStock Split
1.5×2025-03-26
Valuation breakdown
Fair value = median of the applicable methods (Graham، Residual Income، Earnings Power).
Each method below is a different lens on the same company — no single method dominates the result.
Discounted Cash Flow
Excluded — non-positive free cash flow
N/A
Dividend Discount Model
Excluded — company pays no dividend
N/A
Graham Number
A conservative benchmark built from earnings and book value. · Tap to adjust assumptions
1.21
Residual Income (justified P/B)
Values the profit the company earns above the cost of its equity. · Tap to adjust assumptions
0.23
Earnings Power Value
Values today's earning power as-is, assuming no growth. · Tap to adjust assumptions
0.51
DCF only is anchored on FY2025 — the latest year with positive cash flow that supports a value. The other methods (DDM, Graham, RIM, EPV) use current / normalized figures.
Fair Value (median)0.51
▸ Show assumptions▾ Assumptions
- Effective discount rate
- 9.67%
- CAPM cost of equity
- 10.50%
- Risk-free rate
- 4.50%
- Equity risk premium
- 6.00%
- DCF growth (stage 1)
- 8.00%
- DCF terminal growth
- 3.00%
- DCF forecast years
- 5
- DDM dividend growth
- 3.00%
Tune these per company in the Hajras Odoo backend; values recompute automatically.
Wealth simulator
What if you'd invested in Lana Medical regularly?
Starting year
- Invested
- 1K/yr · 4K total(2023 → today · 4 yrs)
- your value today is
- 5.1K SAR
- Total return
- +26.4%(0.0% Dividends · +26.4% Capital gain)
- Annualised (IRR)
- +12.5%
Invested4KSAR
Dividends0SAR
Capital gain1.1KSAR
InvestedCapital gainDividendstap a bar for figures
Major shareholders
As of 2026-06-16Disclosed holders at or above the 5% reporting threshold.
محمد عبدالله عبدالرحمن الشيحه
20.00%
سلمان صالح ابراهيم الفوزان
18.40%
خالد صالح ابراهيم الفوزان
18.40%
Total disclosed56.80%
The Saudi Exchange publishes only holders at or above 5%; smaller stakes are not disclosed.
Community Notes0
No notes yet. Be the first to share a thesis.